Curaleaf Raises Hostile Bid for Aurora to US$5.00/Share with Full Pro Forma Financials
CURLF sits 81% above its 52-week low of $5.4 on elevated volume (3.1× avg).
Summary
Curaleaf raised its hostile bid for Aurora Cannabis by 25% to US$5.00 per share and filed detailed pro forma financials showing the combined company's scale. The tender deadline extends to December 4, 2026.
Key Events · M&A and Partnerships · CURLF
-
Bid Increased 25% to US$5.00/Share
Curaleaf raised its hostile offer for Aurora Cannabis from US$4.00 to US$5.00 per share, comprising US$1.00 cash (up 33%) plus 0.4013 Curaleaf shares, with the cap price raised 20% to US$6.00.
-
Pro Forma Financials Disclosed
The filing includes detailed pro forma statements showing the combined company would have US$1.5 billion in LTM revenue, nearly US$350 million in LTM Adjusted EBITDA, and at least US$40 million in expected annual cost synergies.
-
Deadline Extended to December 4
The tender offer expiry was extended from December 1 to December 4, 2026, giving Aurora shareholders additional time to consider the enhanced terms.
-
86% Premium to Unaffected Price
The enhanced offer represents an 86% premium to Aurora's 30-day VWAP of US$2.75 as of August 10, 2026, and a 217% premium on an ex-cash basis.
Analysis · CURLF · Life Sciences
Curaleaf has increased its hostile takeover bid for Aurora Cannabis by 25% to US$5.00 per share, comprising US$1.00 cash plus 0.4013 Curaleaf shares, with the cap price raised to US$6.00. The tender deadline extends to December 4, 2026. This 425 filing provides the first detailed pro forma financial statements showing the combined company would have US$1.5 billion in LTM revenue, nearly US$350 million in LTM Adjusted EBITDA, and at least US$40 million in annual cost synergies. The filing also reveals preliminary purchase price allocation with goodwill of US$15.6 million and a minimum tender scenario analysis. Aurora's board has recommended rejection, but Curaleaf is escalating pressure with enhanced terms and full financial disclosure.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 44.4% of the 293 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $9.76 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.